Skip to main content
. 2020 Sep 13;21(18):6708. doi: 10.3390/ijms21186708

Figure 2.

Figure 2

Association between clinical features and the tumor angiogenesis score in TCGA and METABRIC breast cancer cohorts. The median was used as a cut-off to divide patients into high and low score groups within each cohort. (A) Boxplots of the angiogenesis score by breast cancer subtype, Nottingham pathological grade, and American Joint Committee on Cancer (AJCC) cancer stage in the TCGA and METABRIC cohort, and AJCC N and M category in TCGA cohort. One-way ANOVA test was used to calculate p values. Tukey type boxplots show median and inter-quartile level values. (B) Pathological complete response (pCR) rate for neoadjuvant chemotherapy between low (blue) and high (red) angiogenesis pathway score in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) and triple negative breast cancer (TNBC) in the GSE20194 (n = 197), GSE25066 (n = 467), and GSE32646 (n = 81) cohorts. Two tailed fisher’s exact test was used to calculate p values.